Prostate Cancer

Prostate Cancer

Active Surveillance

ProVent: Open-Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Phase: 3
Study Product: Sipuleucel-T vs. Active Surveillance
Estimated Study Completion Date: May 2023
ClinicalTrials.gov Identifier: NCT03686683


Radical Prostatectomy

PROTEUS: A Study of ERLEADA (Apalutamide) in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Phase: 3
Study Product: Apalutamide with ADT vs. ADT with placebo
Estimated Study Completion Date: April 22, 2024
ClinicalTrials.gov Identifier: NCT03767244


PSA Relapse

MAP: Muscadine Plus (MPX) In Men With Prostate Cancer

Phase: 3
Study Product: Muscadine Plus
Estimated Study Completion Date: December 2021
ClinicalTrials.gov Identifier: NCT03535675


mCRPC

MAGNITUDE: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Phase: 3
Study Product: Niraparib with Abiraterone Acetate and Prednisone vs. Placebo with Abiraterone Acetate and Prednisone
Estimated Study Completion Date: July 21, 2022
ClinicalTrials.gov Identifier: NCT03748641


TALAPRO-2: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Phase: 3
Study Product: Talazoparib with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03395197


PROpel: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Olaparib with Abiraterone Acetate vs. Placebo with Abiraterone Acetate
Estimated Study Completion Date: August 17, 2022
ClinicalTrials.gov Identifier: NCT03732820


REFMAL 435: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Phase: 1
Study Product: AZD4635 vs. AZD4635 with Durvalumab vs. AZD4635 with Abiraterone Acetate vs. AZD4635 with Enzalutamide
Estimated Study Completion Date: May 13, 2020
ClinicalTrials.gov Identifier: NCT03085095


QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase: 1b/2
Study Product: Niraparib with JNJ-63723283 vs. Niraparib with Abiraterone Acetate
Estimated Study Completion Date: August 31, 2021
ClinicalTrials.gov Identifier: NCT03431350


KEYNOTE-921: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Docetaxel vs. Placebo with Docetaxel
Estimated Study Completion Date: February 28, 2023
ClinicalTrials.gov Identifier: NCT03834506


ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase: 1b/2
Study Product: CPI-1205 with Enzalutamide vs. CPI-1205 with Abiraterone Acetate
Estimated Study Completion Date: August 2020
ClinicalTrials.gov Identifier: NCT03480646


Modra: Study of ModraDoc006 with ritonavir (ModraDoc006/r) vs. I.V. Docetaxel in Metastatic Prostate Cancer

Phase: 2
Study Product: ModraDoc006/r  vs. I.V. Docetaxel
Estimated Study Completion Date: April 1, 2021
ClinicalTrials.gov Identifier: NCT04028388


KEYLYNK-010: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Olaparib vs. Abiraterone Acetate or Enzalutamide
Estimated Study Completion Date: September 30, 2022
ClinicalTrials.gov Identifier: NCT03834519


AstraZeneca AZ5363: A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer

Phase: 1
Study Product: Capivasertib with Abiraterone Acetate vs. Capivasertib with Enzalutamide
Estimated Study Completion Date: UNK
ClinicalTrials.gov Identifier: UNK


KEYNOTE-641: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer

Phase: 3
Study Product: Pembrolizumab with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 12, 2023
ClinicalTrials.gov Identifier: NCT03834493


KEYNOTE-365: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer

Phase: 1b/2
Study Product: Pembrolizumab with Olaparib vs. Pembrolizumab with Abiraterone Acetate
Estimated Study Completion Date: May 18, 2022
ClinicalTrials.gov Identifier: NCT02861573


Galahad: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Phase: 2
Study Product: Niraparib
Estimated Study Completion Date: February 28, 2020
ClinicalTrials.gov Identifier: NCT02854436


TALAPRO-1: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase: 2
Study Product: Talazoparib
Estimated Study Completion Date: March 3, 2022
ClinicalTrials.gov Identifier: NCT03148795


VISION: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Phase: 3
Study Product: 177Lu-PSMA-617 vs. Standard of care
Estimated Study Completion Date: May 2021
ClinicalTrials.gov Identifier: NCT03511664


Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.


Please fill in the form below to email us to learn more about our trials: